Abstract 6402: DNA-PK inhibitor, M3814, as a radiation sensitizer in the treatment of neuroendocrine tumors
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.am2020-6402
Abstract: Despite significant advances in the understanding and managing gastroenteropancreatic neuroendocrine tumors (GEPNETs), the therapeutic success of treatments remains relatively poor. Recent FDA approval of Peptide Receptor Radionuclide Therapy (PRRT) has paved the way for radiation-based… read more here.
Keywords: m3814; treatment; xrt; dna inhibitor ... See more keywords
Abstract 2008: Induced macropinocytosis by DNA-PK inhibitor for KRAS mutant cancer targeting of albumin-binding peptide drug conjugate
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-2008
Abstract: Although Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) is the most well-known tumor driver gene with the highest mutation rate in several types of cancer, there is no effective mutant KRAS targeting drug yet. Recent… read more here.
Keywords: mutant cancer; dna inhibitor; kras mutant; tumor ... See more keywords
DNA-PK Inhibitor Peposertib Amplifies Radiation-Induced Inflammatory Micronucleation and Enhances TGFβ/PD-L1 Targeted Cancer Immunotherapy
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Cancer Research"
DOI: 10.1158/1541-7786.mcr-21-0612
Abstract: Abstract Radiotherapy is the most widely used cancer treatment and improvements in its efficacy and safety are highly sought-after. Peposertib (also known as M3814), a potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor, effectively suppresses… read more here.
Keywords: dna; dna inhibitor; radiation; peposertib ... See more keywords